Update on PharmaPendium August release: Unlocking and sharing critical safety insights (5 Sept 2019) 

Join Elsevier's drug safety marketing Manager Marnix Wieffer to discover the new features of the upcoming PharmaPendium release (week of 19 August) that will support uncovering critical safety insights and effective information sharing. We will discuss:

1. Gain translational insights through improved Boolean operator drug safety searching
2. Streamline information exchange through new sharing searches function
3. Highlight critical post-market data through custom colouring of the FAERS Summary table

What's new in PharmaPendium? -  Introduction to new features released October 31 2018 (November 2018)
Join PharmaPendium Product Manager Pooja Jain to discover the new features that facilitate efficient translational studies of drug safety and efficacy.
Watch the recording here

Finding information that matters in PharmaPendium — An introduction (July 11, 2018)
This webinar covered in-depth information and included demonstrations of how to leverage FDA and EMA drug approval data to inform critical drug-development decisions. It discussed how PharmaPendium content and taxonomies support informed decision-making, how to use the FAERS search form to detect post-market safety concerns and the types of questions you can find answers to by searching the drug safety, efficacy, pharmacokinetic and metabolising enzyme modules in PharmaPendium.
Watch the recording here
Download slides (pdf)

Reducing efficacy-related risks with PharmaPendium (May 22, 2018)
This webinar covered in-depth information and demonstrations of how to leverage the extracted efficacy data from FDA and EMA drug approval documents to reduce the risk of late-stage clinical trial failures.
Watch the recording here
Download slides (pdf)

Identifying Drug-Drug Interactions using PharmaPendium (May 2, 2018)
Successful drug development requires anticipating safety and regulatory issues as early as possible. This webinar discussed how to leverage PharmaPendium's comparative pharmacokinetic, metabolising enzyme and transporter information from FDA and EMA drug approval documents, FDA Advisory committee meeting reports, and literature – along with a powerful DDI Risk calculator – to predict, identify and assess potential drug-drug interactions.
Watch the recording here
Download slides (pdf)

Leverage Pharmacokinetic data in PharmaPendium to inform drug development strategies (March 2018)
Pharmacokinetic information from FDA and EMA regulatory documents informs translational and clinical development decisions and may lead to more successful drug development and regulatory approval strategies.
This webinar demonstrated how to leverage comparative pharmacokinetic information from FDA and EMA Drug Approval documents to make better-informed decisions on which drugs have the most potential to succeed in clinical development.
Watch the recording here
Download slides (pdf)

Supporting Drug Safety with PharmaPendium and advanced FAERS searching (February 2018)
Drug safety considerations impact the entire drug development lifecycle, from preclinical safety assessments to clinical trials to post-market.
This webinar discussed how to leverage the comparative FDA and EMA regulatory information in PharmaPendium to inform translational and clinical development decisions, as well as to strengthen regulatory approval strategies
Watch the recording here
Download slides (pdf)